TRCT
SLRN

Tower Research Capital (TRC)’s ACELYRIN SLRN Stock Holding History

Tower Research Capital (TRC)’s Portfolio SLRN Stock Details SLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,637
Closed -$8.98K – 5549
2025
Q1 		$8.98K Sell
3,637
-3,260
-47% -$7.75K ﹤0.01% 3838
2024
Q4 		$21.7K Buy
6,897
+2,971
+76% +$14.4K ﹤0.01% 3127
2024
Q3 		$19.4K Sell
3,926
-6,774
-63% -$35K ﹤0.01% 3254
2024
Q2 		$47.2K Buy
10,700
+10,354
+2,992% +$48.5K ﹤0.01% 3151
2024
Q1 		$2.34K Sell
346
-28,935
-99% -$220K ﹤0.01% 5064
2023
Q4 		$218K Buy
29,281
+27,041
+1,207% +$231K ﹤0.01% 2030
2023
Q3 		$22.8K Sell
2,240
-845
-27% -$17.9K ﹤0.01% 3260
2023
Q2 		$64.5K Buy
+3,085
New +$63.1K ﹤0.01% 2373

Other funds holding SLRN

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Tower Research Capital (TRC)'s SLRN Position: Q2 2025 in Review

Tower Research Capital (TRC) sold out of ACELYRIN (SLRN) in Q2 2025, closing a stake of 3,637 shares — an estimated $8.98K sold.

Tower Research Capital (TRC) first reported a position in SLRN in Q2 2023 and held it in 8 quarters. The position peaked at $218K in Q4 2023. 2 funds tracked by Wall St. Rank hold SLRN as of Q2 2025.

  • Tower Research Capital (TRC) reported no remaining ACELYRIN position as of Q2 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 3,637 ACELYRIN shares in Q2 2025, an estimated $8.98K.
  • Tower Research Capital (TRC) first reported a position in ACELYRIN in Q2 2023 and held it in 8 quarters.
  • Tower Research Capital (TRC)'s ACELYRIN position peaked at $218K in Q4 2023.
  • 2 funds tracked by Wall St. Rank held ACELYRIN as of Q2 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2025, filed 15 Aug 2025.